Drug-eluting stents (DES) have gained widespread adoption being implanted in over 6 million patients worldwide demonstrating significant improvements in clinical efficacy combined with comparable safety to bare metal stents.
We must optimize stent deployment & maintain a registry of how well (or poorly) we use drug-eluting stents. Instead of asking “Which stent?” or “How much anti-platelet therapy?” we must ask “How effectively are we deploying our stents?”
Martin Leon, M.D., a leading interventional cardiologist accused of leaking details of a major study weeks before its scheduled release, was barred today from taking part in next year's American College of Cardiology meeting.
Martin B. Leon, MD, violated academic ethics of the highest order by leaking results of the COURAGE trial prematurely, denigrating its design, discrediting its results, to protect pocketbooks of interventional cardiologists and stent industry. Sanctions
An investigational bioabsorbable coronary artery stent, in its first human trials, showed acceptable safety, with efficacy better than bare-metal devices but well short of drug-eluting devices, Dutch researchers said here.
An investigational drug-eluting stent called Xience, coated with everolimus, led to significantly less late lumen loss after nine months than did the Taxus (paclitaxel-eluting) stent, said researchers here today. March 2007
An investigational bioabsorbable magnesium coronary stent worked as advertised for several months but led to a higher revascularization rate at one year.